PRO-CEFUROXIME - 500 TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
23-09-2019
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
CEFUROXIME (CEFUROXIME AXETIL)
Tillgänglig från:
PRO DOC LIMITEE
ATC-kod:
J01DC02
INN (International namn):
CEFUROXIME
Dos:
500MG
Läkemedelsform:
TABLET
Sammansättning:
CEFUROXIME (CEFUROXIME AXETIL) 500MG
Administreringssätt:
ORAL
Enheter i paketet:
100
Receptbelagda typ:
Prescription
Terapiområde:
SECOND GENERATION CEPHALOSPORINS
Produktsammanfattning:
Active ingredient group (AIG) number: 0122448002; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2021-05-31
Produktens egenskaper
Page 1 of 27
PRODUCT MONOGRAPH
PR
PRO-CEFUROXIME - 500
CEFUROXIME AXETIL TABLETS, USP
500 MG CEFUROXIME / TABLET
ANTIBIOTIC
PRO DOC LTÉE
DATE OF REVISION:
2925, boul. Industriel
September 23, 2019
Laval, Quebec
H7L 3W9
CONTROL NO.: 229806
Page 2 of 27
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
.......................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
......................................................................................................
6
DRUG INTERACTIONS
.......................................................................................................
7
DOSAGE AND ADMINISTRATION
......................................................................................
8
OVERDOSAGE
....................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
9
STORAGE AND
STABILITY.................................................................................................
9
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 9
PART II: SCIENTIFIC INFORMATION
....................................................................................10
PHARMACEUTICAL INFORMATION
..................................................................................10
CLINICAL TRIALS
...............................................................................................................11
DETAILED PHARMACOLOGY
....
Läs hela dokumentet
